The TORCH (TOwards a Revolution in COPD Health) study: salmeterol/ fluticasone propionate (SFC) is well tolerated in patients with COPD over three years Source: Eur Respir J 2006; 28: Suppl. 50, 34s Year: 2006
Eligibility for mepolizumab, omalizumab and reslizumab in the EU population: The IDEAL study Source: International Congress 2016 – Asthma: treatment, disease control, and quality of life Year: 2016
Efficacy of once-daily tiotropium Respimat in adults with asthma based on GINA Steps 2–5 Source: International Congress 2017 – Bronchial asthma management Year: 2017
Asthma control in asthmatics treated with extrafine or non-extrafine ICS/LABA combinations in real life setting Source: Annual Congress 2013 –Diagnosis and management of respiratory diseases Year: 2013
Fluticasone propionate/formoterol therapy for asthmatic patients: Results of a non-interventional study Source: International Congress 2016 – Asthma management Year: 2016
Impact of adherence to fluticasone propionate/salmeterol combination (FSC) therapy on the outcomes of patients with asthma: A population based study Source: Annual Congress 2013 –Treatment and adherence to treatment of respiratory disease Year: 2013
Device handling study of a novel fluticasone propionate/formoterol breath-triggered inhaler Source: International Congress 2016 – Pulmonary drug delivery Year: 2016
Efficacy and safety of fluticasone propionate/formoterol in paediatric patients with asthma Source: International Congress 2014 – Paediatric asthma: pharmacological and non-pharmacological management Year: 2014
Assessment of the bioequivalence of two DPIs containing fluticasone and salmeterol, in patients with controlled or partly controlled asthma Source: International Congress 2016 – Clinical characteristics of asthma Year: 2016
Asthma control using a combination of mometasone furoate/formoterol: Grouped analysis of three clinical trials Source: Annual Congress 2010 - Combination therapy in asthma and COPD Year: 2010
Plume characteristics of fluticasone propionate/formoterol pMDI compared with fluticasone propionate/salmeterol pMDI Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013
Health care resource utilization following addition of montelukast or salmeterol to fluticasone in patients with inadequately controlled asthma (IMPACT trial) Source: Eur Respir J 2004; 24: Suppl. 48, 127s Year: 2004
Health status changes in COPD patients after real-life switch from tiotropium or salmeterol/fluticasone to indacaterol/glycopyrronium using the EQ-5D-3L instrument: results from the POWER study Source: International Congress 2018 – COPD management Year: 2018
Safety of formoterol in asthma clinical trials: an update Source: Eur Respir J 2014; 43: 103-114 Year: 2004
Late Breaking Abstract - A randomized clinical study to assess the impact of budesonide/formoterol (BUD/FM) pMDI medication reminders on adherence in COPD patients Source: International Congress 2018 – Integrating pharmacological and non-pharmacological management in COPD: are we there yet? Year: 2018
INSTEAD: Randomized switch trial of indacaterol and salmeterol/fluticasone combination (SFC) in moderate COPD: Symptoms results Source: International Congress 2015 – New data on established treatments for asthma and COPD Year: 2015
Late Breaking Abstract - Effectiveness of Fluticasone furoate/vilanterol (FF/VI) compared to usual care (UC) in patients with asthma: The Salford Lung Study (SLS) Source: International Congress 2017 – Late-breaking studies in asthma and COPD Year: 2017
Real-life effectiveness of budesonide/formoterol for the management of asthma and COPD Source: International Congress 2016 – Clinical characteristics of asthma Year: 2016
Clinical effectiveness of once-daily fluticasone furoate/umeclidinium/vilanterol in usual practice: the COPD INTREPID study design Source: ERJ Open Res, 5 (4) 00061-2019; 10.1183/23120541.00061-2019 Year: 2019
Formoterol turbuhaler compared with salbutamol as reliever medication in asthma: a worldwide, randomised, effectiveness trial (RELIEF Study) Source: Eur Respir J 2002; 20: Suppl. 38, 44s Year: 2002